Clinical Trial Detail

NCT ID NCT03672539
Title Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Gemtuzumab ozogamicin

CPX-351 + Gemtuzumab ozogamicin

Age Groups: senior adult

No variant requirements are available.